KA-5377 / KYinno - LARVOL DELTA

The bispecific antibody KA-5377, targeting CD19 and 4-1BB, specifically enhances T cell activity against lymphoma (AACR 2025) - "The difference in EC50 (effective concentration for 50% activation) between the CD19-bound and non-bound states is approximately 100-fold, compared to only a 2-fold difference observed with the benchmark bispecific antibody Englumafusp Alfa.When combined with a low concentration of CD3 antibody to stimulate T cell activation, KA-5377 significantly enhances T cell activation and proliferation in co-culture assays using primary T cells isolated from human PBMCs. Toxicity studies are currently ongoing. In conclusion, KA-5377, developed using our nanobody antibody discovery platform, represents a promising preclinical candidate for the treatment of Relapsed/Refractory B-cell lymphoma."

IO biomarker • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19